Armata Pharmaceuticals (ARMP) Expected to Release Earnings on Wednesday

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) is expected to be announcing its Q3 2026 resultson Wednesday, November 11th. Analysts expect Armata Pharmaceuticals to post earnings of ($0.57) per share and revenue of $0.45 million for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.27) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.17. The business had revenue of $2.51 million for the quarter, compared to analysts’ expectations of $0.40 million. Armata Pharmaceuticals had a negative net margin of 3,467.04% and a negative return on equity of 12.24%. On average, analysts expect Armata Pharmaceuticals to post $0.50 EPS for the current fiscal year and ($2.04) EPS for the next fiscal year.

Armata Pharmaceuticals Trading Up 8.4%

Shares of ARMP opened at $3.09 on Wednesday. Armata Pharmaceuticals has a 52-week low of $2.74 and a 52-week high of $14.98. The company has a 50-day simple moving average of $4.10 and a 200-day simple moving average of $6.95.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price on shares of Armata Pharmaceuticals in a report on Tuesday, September 22nd. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $15.00.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing targeted bacteriophage therapies for drug-resistant bacterial infections. Bacteriophages, or phages, are viruses that selectively infect and destroy specific bacteria, offering a potential alternative or complement to conventional antibiotics.

The company’s pipeline has included inhaled and intravenously administered phage candidates designed to treat serious infections caused by pathogens such as Pseudomonas aeruginosa and Staphylococcus aureus.